FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study
Status:
Withdrawn
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The available treatments for patients with mood and anxiety spectrum disorders have
significant limitations. This study will contribute significantly to public health by taking
steps to address these limitations by aiding in the interpretation of a study that: 1) tests
a promising new treatment for mood and anxiety spectrum disorders; 2) evaluates a potential
target in the brain which could serve as the basis for development of additional new
candidate compounds for the treatment of patients with mood and anxiety spectrum disorders;
3) establishes more expeditious methods for evaluating potential new therapies for patients
with mood and anxiety spectrum disorders; and 4) specifically establishes methods for the
development of new therapies targeting anhedonia, an important RDoC (Research Domain
Criteria) endpoint.